Who is sponsoring NCT04469634?

NCT04469634 is sponsored by Institute of Tropical Medicine, Belgium.

What condition does NCT04469634 study?

NCT04469634 studies SARS-CoV2, COVID-19.

Is NCT04469634 still recruiting?

NCT04469634 is currently completed. Last updated 6 March 2023.

Last reviewed 2023-03-06 · How we verify

NCT04469634: ImmCoV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?

Completed NA Last updated 6 March 2023

What this trial tests

NA trial testing Assessing antibody responses, neutralizing capacity and memory B-cell function in SARS-CoV2 in 150 participants. Completed in 31 December 2022.

Timeline

31 July 2020

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Institute of Tropical Medicine, Belgium
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	150
Start date	31 July 2020
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	2 locations across Belgium

Drugs / interventions tested

Assessing antibody responses, neutralizing capacity and memory B-cell function

Conditions studied

SARS-CoV2 — all drugs for SARS-CoV2 →
COVID-19 — all drugs for COVID-19 →

Sponsor

Institute of Tropical Medicine, Belgium

Who can join

Adults 18 to 99, any sex, with SARS-CoV2 or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objectives of this study are (1) to determine the ex vivo neutralizing capacity and the longevity of SARS-CoV-2-specific Ab responses and (2) to measure the memory B-cell responses in a cohort of health care workers (HCW) recovering from severe, mild or asymptomatic infection. By focusing on HCW, a population that is at risk for re-infection during a second epidemic wave, the correlation between nAb levels and protection is investigated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Institute of Tropical Medicine, Belgium trials

Trials by the same sponsor.

NCT07463040 — Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL) · Phase 3 · not yet recruiting
NCT07174648 — Testing of a New Rapid Antigen Test for Plague in Ituri, Democratic Republic of the Congo. · not yet recruiting
NCT07499739 — Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX) · Phase 4 · not yet recruiting
NCT07342829 — Prospective Follow-up After MVA-BN Booster Vaccination · not yet recruiting
NCT06839989 — An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04469634 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Tropical Medicine, Belgium
Last refreshed: 6 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04469634.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing